How does AKUMS's PE Ratio compare to its peers?

AKUMS is good value based on its Price-To-Earnings Ratio (32.5x) compared to the peer average (54.2x).

How does AKUMS's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

AKUMS is expensive based on its Price-To-Earnings Ratio (32.5x) compared to the Asian Life Sciences industry average (31.8x).

What is AKUMS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate AKUMS's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of AKUMS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

AKUMS (₹572.8) is trading below our estimate of [[fair value]] (₹781.71)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

AKUMS Stock Overview

Manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. More details

AKUMS fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 26.7% below our estimate of its fair value

Became profitable this year

Risk Analysis

No risks detected for AKUMS from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Akums Drugs and Pharmaceuticals Limited Competitors

Indegene

NSEI:INDGN

₹140.6b

Innova Captab

NSEI:INNOVACAP

₹56.0b

Syngene International

NSEI:SYNGENE

₹338.7b

Tarsons Products

NSEI:TARSONS

₹21.3b

Price History & Performance

Summary of share price highs, lows and changes for Akums Drugs and Pharmaceuticals
Historical stock prices
Current Share Price	₹572.80
52 Week High	₹1,175.90
52 Week Low	₹530.05
Beta	0
1 Month Change	-1.35%
3 Month Change	-32.75%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-28.06%

Recent updates

Shareholder Returns

	AKUMS	IN Life Sciences	IN Market
7D	-2.8%	-1.3%	-4.2%
1Y	n/a	49.7%	19.1%

Return vs Industry: Insufficient data to determine how AKUMS performed against the Indian Life Sciences industry.

Return vs Market: Insufficient data to determine how AKUMS performed against the Indian Market.

Price Volatility

Is AKUMS's price volatile compared to industry and market?
AKUMS volatility
AKUMS Average Weekly Movement	7.1%
Life Sciences Industry Average Movement	6.2%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.0%
10% least volatile stocks in IN Market	4.1%

Stable Share Price: AKUMS has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: Insufficient data to determine AKUMS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2004	7,388	Sanjeev Jain	www.akums.in

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. It offers dosage forms, such as tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form fill seals, topical preparations, eye drops, dry powder injections, rotacaps and gummies, and others. The company operates as pharmaceutical contract development and manufacturing company.

Akums Drugs and Pharmaceuticals Limited Fundamentals Summary

How do Akums Drugs and Pharmaceuticals's earnings and revenue compare to its market cap?
AKUMS fundamental statistics
Market cap	₹90.16b
Earnings (TTM)	₹2.78b
Revenue (TTM)	₹40.83b

32.5x

P/E Ratio

2.2x

P/S Ratio

Is AKUMS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AKUMS income statement (TTM)
Revenue	₹40.83b
Cost of Revenue	₹25.17b
Gross Profit	₹15.66b
Other Expenses	₹12.88b
Earnings	₹2.78b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	17.65
Gross Margin	38.35%
Net Profit Margin	6.80%
Debt/Equity Ratio	16.1%

How did AKUMS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 01:02
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Akums Drugs and Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution